Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.
Risk & Volatility
Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its share price is 201% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.82, suggesting that its share price is 182% less volatile than the S&P 500.
Valuation & Earnings
This table compares Madrigal Pharmaceuticals and Kiora Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Madrigal Pharmaceuticals | $180.13 million | 58.59 | -$465.89 million | ($13.01) | -35.72 |
| Kiora Pharmaceuticals | $16.02 million | 0.48 | $3.60 million | ($2.09) | -1.00 |
Kiora Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Madrigal Pharmaceuticals and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Madrigal Pharmaceuticals | -39.04% | -41.50% | -26.18% |
| Kiora Pharmaceuticals | N/A | -36.35% | -25.82% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Madrigal Pharmaceuticals and Kiora Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Madrigal Pharmaceuticals | 2 | 2 | 13 | 1 | 2.72 |
| Kiora Pharmaceuticals | 1 | 1 | 1 | 0 | 2.00 |
Madrigal Pharmaceuticals presently has a consensus price target of $654.73, indicating a potential upside of 40.89%. Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 380.77%. Given Kiora Pharmaceuticals’ higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.
Institutional and Insider Ownership
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Kiora Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
